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Abstract: Cyanobacteria (blue-green algae) are abundant in fresh, brackish and marine 
waters worldwide. When toxins produced by cyanobacteria are present in the aquatic 
environment, seafood harvested from these waters may present a health hazard to 
consumers. Toxicity hazards from seafood have been internationally recognised when the 
source is from marine algae (dinoflagellates and diatoms), but to date few risk assessments 
for cyanobacterial toxins in seafood have been presented. This paper estimates risk from 
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seafood contaminated by cyanobacterial toxins, and provides guidelines for safe human 
consumption. 
Keywords: cyanobacteria; blue-green algae; toxins; seafood safety; health guidelines 
 
1. Introduction 
The Gippsland Lakes are a system of coastal lagoons situated in southeast of Victoria (Australia), 
approximately 200 km east of Melbourne and are important for recreational, tourist and commercial 
activities. The Lakes are a commercial seafood source, including shellfish, crustaceans and fish, as 
well as providing popular recreational fisheries. Considerable modifications to the Lakes catchments 
have occurred since European settlement with agricultural and fisheries development, including the 
creation of a permanently open entrance to Bass Straight in 1889. This environment, which was once a 
freshwater lake, is now a more saline, high nutrient region, and cyanobacterial (blue-green algal) 
blooms have now become a common occurrence. Since 1985, there have been seven   
non-cyanobacterial blooms recorded in the Lakes (usually diatoms or dinoflagellates), and   
12 cyanobacterial blooms [1]. Nodularia spumigena is the most frequent cyanobacterium to bloom, 
with sporadic Anabaena circinalis and Microcystis aeruginosa blooms. 
Cyanobacterial blooms are largely dependent on nutrient availability and water temperature, and the 
predominant species affected by salinity. Warmer waters during summer accelerate growth of the 
organisms [2]. Cyanobacterial blooms are a public health concern because the toxins that some species 
of cyanobacteria produce can have harmful effects on consumers, whether this is through drinking 
water, recreational exposure or from seafood. All three common bloom-forming cyanobacteria in the 
Gippsland lakes are toxic species. Nodularia spumigena, which is abundant in the Lakes, was the first 
cyanobacterium to be identified in the scientific literature as the cause of livestock poisoning in 1878 [3]. 
Cyanobacterial toxins have been shown to bioaccumulate in aquatic organisms such as shellfish, 
prawns and fish, and have previously resulted in restrictions on the collection of these organisms from 
the Gippsland Lakes [4,5]. In many cases the toxicity is sublethal to these aquatic species, which 
allows the animals to survive long enough to accumulate toxins and transfer them along the food  
chain [4]. It is possible that the concentration of cyanobacterial toxins in seafood can reach levels at 
which human consumption should be discouraged [6]. With the exception of the worldwide adoption 
of guideline levels for saxitoxins in seafood (for example based on Food Standards Australia New 
Zealand (FSANZ) Food Standard 1.4.1), there are no national guidelines that advise on safe levels of 
cyanobacterial toxins in seafood. 
In order to provide advice and to define acceptable levels of cyanobacterial toxins in seafood in 
Victoria, Australia, the Victorian Department of Health convened a scientific advisory group to carry 
out a risk assessment regarding commercial and recreational seafood safety in the Gippsland Lakes. 
The seafoods of concern were fish, prawns and mussels harvested from the lakes. The identified toxins 
for the risk assessment were microcystins, nodularin, saxitoxins and cylindrospermopsin, all of which 
have been found in Australian aquatic environments and are distributed worldwide [6]. 
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2. Methods, Results and Discussion 
2.1. Risk Assessment Methodology 
The standard human health risk assessment approach was employed, which incorporates the 
following steps: 
(1)  Hazard identification—qualitative determination of the potential of a chemical or agent to 
cause adverse effects in humans. 
(2)  Dose-response assessment—examination of the quantitative relationship between the hazard 
at different exposure levels and the incidence of adverse effects in humans or other animals. 
(3)  Exposure assessment—determination of the route, frequency and duration of the exposure, 
including the nature of exposed populations. 
(4)  Risk characterisation—integration of hazard presence, dose-response  and exposure 
assessment information. 
2.2. Hazard Identification  
In carrying out the hazard identification and dose-response assessment of cyanobacterial toxins in 
seafood, the majority of relevant studies identified had been undertaken on saxitoxins of marine 
dinoflagellate origin, with few reported cases of human cyanobacterial toxicity associated with seafood 
consumption [7]. In addition, none of the reported cases detailed the adverse effects in humans as a 
function of dose. However human toxicity from cyanobacterial toxin contamination of dialysis fluid, 
drinking water and recreational water consumption has been demonstrated.  
2.3. Dose-Response Assessment  
With no direct information regarding the human health risks of cyanobacterial toxins in seafood as a 
function of degree of exposure (dose-response), it is necessary to extrapolate information from animal 
toxicity studies. There are several different types of animal studies used to identify hazards and to 
assess the dose-response. They include acute, sub-chronic, chronic, reproductive and developmental 
toxicity, as well as genotoxicity studies [8]. As only oral exposure is relevant when considering toxin 
exposure from seafood, animal studies in the published literature that were conducted in accordance 
with the OECD 1998 Guideline for the Testing of Chemicals for sub-chronic oral toxicity were 
assessed [8,9]. Where possible, experimental data from two species, one rodent and one non-rodent, 
was used. 
To determine the safe dose of potentially toxic materials in the diet, toxicological data is used to 
calculate a Tolerable Daily Intake (TDI). This is an estimate of the intake of a substance which is 
without appreciable health risk to consumers over their lifetime. However, as the cyanobacterial toxins 
are acutely toxic and consumers may eat large portion sizes on occasions, it is also appropriate to 
consider establishing an acute reference dose (ARfD). The ARfD is an estimate of “the amount a 
substance in food or drinking water, normally expressed on a body weight basis that can be ingested in 
a period of 24 hours or less without appreciable health risks to the consumer on the basis of all known 
facts at the time of the evaluation” [10]. The ARfD is used to assess the dietary risk for those Int. J. Environ. Res. Public Health 2012, 9 
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consumers who eat high levels of seafood in a single meal or over a single day, while the TDI is used 
to assess the dietary risk for those consumers that eat the average level of seafood over a lifetime. Both 
the TDI and ARfD are calculated from experimental data for the intake of the substance which has no 
detectable adverse health effects, called the No Observed Adverse Effect Level (NOAEL). 
Uncertainty factors are applied to the NOAEL to allow for variations in individual sensitivity, 
extrapolation between human and animal studies and to account for uncertainties in data. The standard 
factors are 10 for intraspecies (within human) variability, 10 for interspecies (rodent compared to 
human) variability, and an additional (third) variable factor for limitations in data. Limitations in the 
data that this additional factor may account for include: the use of only one sex or species of animal; 
possibility of mutagenicity or carcinogenicity; teratogenicity or reproductive toxicity. In the derivation 
of all health guideline values for cyanobacterial toxins in seafood (refer to Section 3 below) this 
additional factor was assigned a value of 2. For each of the toxins the limitations in the data that 
necessitated this value of 2 varied (see below). It should be noted, however, that for none of the toxins 
did this value aim to allow for the fact the toxicity trials were sub-chronic rather than lifetime. For 
these toxins this was not regarded as a limitation in the data because the seasonality and irregularity of 
toxic cyanobacterial blooms mean that human exposure to the toxins will be acute to sub-chronic. For 
each of the toxins the total uncertainty factor used in the derivation of the health guideline values  
was 200 (10 × 10 × 2) 
2.4. Exposure Assessment 
To convert the TDI or ARfD into a health guideline value in seafood it is necessary to undertake an 
exposure assessment to incorporate information including the bodyweight of consumers; the quantity 
of seafood consumed; and whether the consumer may be exposed to the toxin via other sources (for 
example, through drinking water or through recreational activities). Average body weights for specific 
age groups (that is 17 years or above and 2–16 years) were sourced from recent national nutritional 
surveys [11,12]. For acute dietary risk assessment purposes and to protect consumers of high levels of 
seafood, data on the high-level consumption of fin fish, prawns and molluscs (97.5th percentile intake) 
were extracted from the 1995 National Nutrition Survey (NNS) 1 for consumers aged 17 years and 
above (Table 1). For children aged 2–16 years, the more recent 2007 Australian National Children’s 
Nutrition and Physical Activity Survey 2 was used (Table 1). 
It is not possible to establish generic health guideline values which would be applicable to other 
regions of the world because seafood consumption patterns can vary considerably. However, if average 
bodyweights and high-level consumption data are available then it is possible to use the outlined 
procedure to derive relevant health guideline values for other countries where seafood consumption 
patterns differ substantially from Australia and New Zealand. 
   Int. J. Environ. Res. Public Health 2012, 9 
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Table 1. High level seafood consumption (97.5th percentile). 
Age group 
(years) 
Commodity 
Consumer intake 
4 
g/kg BW 
5/day 
g/day  Survey 
1,2 
≥17  Fish (diadromous and freshwater) 
3  5.1  377  1995 
  Prawns  5.1  377   
  Mussels  2.4  178   
2–16  Fish (diadromous and freshwater  8.4  319  2007 
  Prawns  6.2  236   
  Molluscs 
6  3.9  148   
Notes: 
1 1995 National Nutrition Survey of Australia (1995 NNS), surveying 13858 people aged 2 
years and over. This survey used one 24-hour recall for all respondents and a second 24-hour recall 
for approximately 10% of respondents [11]; 
2 2007 Australian National Children’s Nutrition and 
Physical Activity Survey (2007 NCS), surveying 4487 people aged 2–16 years. The survey used 
two 24-hr recalls for all respondents. For the purposes of estimating acute dietary exposures only a 
single day 24-hour recall is used [12]; 
3 Diadromous and freshwater fish consumption excluding all 
marine fish; 
4 The food consumption data outlined in the table includes the amount consumed alone 
and as an ingredient in mixed foods. In DIAMOND, FSANZ’s dietary exposure assessment 
computer program, all mixed foods have a recipe and these recipes were used to break down mixed 
foods into their raw commodity components. For example fish contained in a fish casserole are 
included in fish consumption; 
5 Bodyweights: 74 kg > 17 years; 38 kg 2–16 years; 
6 Consumption 
amounts for molluscs were used where there were insufficient consumers of mussels alone to 
derive a valid 97.5th percentile consumption value. There were only 11 consumers of mussels in 
the 2–16 year age group dataset. “Molluscs” includes mussels, octopus, oysters, scallops and squid. 
2.5. Allocation Factor 
In the context of this report the allocation factor is defined as the proportion of toxin exposure 
gained through the consumption of seafood. The only likely route of public exposure to cyanobacterial 
toxins would be through the consumption of seafood. Drinking water is not sourced from the 
Gippsland Lakes and recreational use of the lakes is strongly advised against as soon as a significant 
cyanobacterial bloom occurs, as per the Guidelines for Managing Risks in Recreational Water [13].  
An allocation factor of one (or 100% of toxin exposure gained through consumption of seafood) was 
therefore deemed appropriate. 
2.6. Risk Characterisation 
It is appropriate to consider the acute dietary risks posed by the presence of cyanobacterial toxins in 
seafood as they are acutely toxic and consumers may eat large portion sizes on occasions. Therefore, 
the establishment of maximum levels (MLs) for seafood should ideally be based on an acute dietary 
risk characterisation, which would be suitably protective of excessive chronic exposures as the target 
organ is the same following either a single or repeated dietary exposure. 
There is a paucity of data on the thresholds of acute oral toxicity for cyanobacterial toxins and 
therefore limited potential to establish an ARfD for cylindrospermopsin and microcystins. On this 
basis, a conservative approach has been taken where the high-level intake (the 97.5th percentile intake) Int. J. Environ. Res. Public Health 2012, 9 
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of fin fish, prawns or mussels or molluscs have been compared with the TDI. Two population groups 
have been assessed; 17 years and above and 2–16 year olds. For the saxitoxins (STXs), no acute 
dietary risk characterisation has been undertaken because the current Australian and New Zealand ML 
has proven to be an effective risk management limit. 
By integrating the hazard identification, dose-response and exposure assessment information, health 
guideline values for cylindrospermopsin and microcystins in seafood can be derived. The steps are as 
follows:  
Step 1: Determine the TDI (μg/kg bw/day): 
TDI (μg/kg bw/day) = No Observable Adverse Effect Level ÷ Uncertainty Factors  (1) 
Step 2: Determine the acceptable limit of toxin consumption per person per day (μg/day): 
Acceptable limit (μg/day) = TDI (or ARfD) × average bodyweight (kg) × allocation factor  (2) 
Step 3: Define the high level intake of seafood per consumer per day (kg/day). 
Step 4: Derive health guideline level for toxin in seafood: 
Guideline value (μg/kg) = Acceptable limit (μg/day) ÷ consumption of seafood per day (kg/day)  (3) 
Health guideline values need to be derived for each cyanobacterial toxin separately (using specific 
TDI or ARfD values) and then for each seafood (fish, prawns and mussels or molluscs) separately 
(using different average consumption values).  
3. Derivation of Health Guideline Values 
3.1. Cylindrospermopsin 
Cylindrospermopsin (CYN) occurs in fresh and brackish waters worldwide, due to the presence of 
the cyanobacterial genera Cylindrospermopsis, Aphanizomenon, Anabaena, Raphidiopis, Lyngbya and 
Umezakia [14]. 
Studies of bioaccumulation of cylindrospermopsin in gastropod snails, bivalves [15], crustaceans [16], 
amphibian tadpoles and fish [17] demonstrated that this toxin is concentrated into tissues from free 
solution and from toxic Cylindrospermopsis cells. The highest accumulation was seen in mussels with 
a whole-body concentration of almost 3 mg/kg dry weight, with the maximum tissue concentration 
found in haemolymph. Cylindrospermopsin appears in muscle tissue as well as viscera, increasing the 
possibility of consumption in these seafoods. 
Human poisoning from CYN has been previously recorded. In Palm Island in 1979, for example, 
150 people received hospital treatment for an unusual hepatoenteritis after drinking water from a 
reservoir that was treated with copper to remove a Cylindrospermopsis algal bloom [18]. The absence 
of toxin exposure information, however, makes this case unusable for the purposes of deriving a TDI. 
There have, however, been several published accounts of the oral toxicity of cylindrospermopsin in 
animals, with the majority of studies using a single dose [19–21]. Repeat oral dosing after a two week 
interval showed unexpectedly enhanced toxicity, indicating residual damage to the animals from the 
first dose [22]. Int. J. Environ. Res. Public Health 2012, 9 
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A study by Humpage and Falconer [23], following the protocols set out by the OECD for 
subchronic oral toxicity assessment in rodents, exposed male Swiss Albino mice to 
cylindrospermopsin through drinking water and through gavage (dosing by mouth) [9]. The first trial 
used a cylindrospermopsin-containing extract from cultured Cylindrospermopsis raciborskii, supplied 
in drinking water for 10 weeks. The dose of cylindrospermopsin ranged from 0 to 657 μg/kg/day at  
4 levels. The animals were examined clinically during the trial and showed no ill effects other than a 
small dose-related decrease in body weight compared to controls after 10 weeks. Liver and kidney 
weights were significantly higher with increasing dose. Several  biochemical indicators of liver 
function showed dose-related changes. For instance, serum total bilirubin and albumin increased, while 
serum bile acids decreased. Liver enzyme changes in the serum showed a different pattern to those 
seen with acute liver poisoning or hepatitis, as only a small increase in serum alanine aminotransferase 
and a larger increase in alkaline phosphatase were observed. There was also a decrease in aspartate 
aminotransferase. The most substantial change observed was in the urine protein/creatinine 
concentration, which decreased sharply with dose. This was interpreted as reflecting decreased protein 
synthesis in the kidney through inhibition by the toxin. Histopathological examination of all internal 
organs showed changes only in the liver and kidney. Dose-related hepatocyte damage and renal 
proximal tubule necrosis were observed [23]. 
When it was apparent from these results that lower oral doses were required to find the No 
Observed Adverse Effect Level, Humpage and Falconer [23] carried out a second trial in which mice 
were  dosed  orally  by  gavage  over  11  weeks  with  0,  30,  60,  120  and  240  μg/kg/day  of  purified 
cylindrospermopsin. The same trends in serum parameters were seen, but with no statistically significant 
changes. Organ weights showed most sensitivity to these low doses with significant increases in body 
weight, and as a percentage of body weight, in liver, kidney, adrenal glands and testis. Minor 
histopathological damage was seen in the liver at the two upper dose levels, and in kidney proximal 
tubules at the highest dose. Urine protein/creatinine decreased progressively with dose, reaching 
significance at 120 μg/kg/day of oral cylindrospermopsin. 
At very low dose levels of toxins compensatory changes occur in metabolism to restore homeostasis. 
The increases in organ weight can be expected to compensate for reductions in function as seen in the 
liver and kidneys, and compensation for stresses resulting from the toxin, for example in the adrenal 
glands. It therefore becomes subjective to decide where the No Observed Adverse Effect Level occurs, 
depending on which effect is considered adverse. From the urine protein data it is clear that the 
NOAEL is below 120 μg/kg/day. However statistically significant change in kidney weight occurred  
at 60 μg/kg/day.Thus to adopt the conservative viewpoint that the most sensitive response should be 
considered as the indicator of adverse effect, the dose of 30 μg/kg/day was accepted as the NOAEL 
from these trials [23]. Recent studies have corroborated this value and shown that both males and 
females are affected to a similar degree [24]. 
Thus using 30 μg/kg/day as the NOAEL, the TDI for cylindrospermopsin can be calculated. 
TDI(μg/kg/day) = 30 ÷ Uncertainty factors  (4) 
The uncertainty factors are 10 for intraspecies variability, 10 for interspecies variability and an 
additional factor of 2 given that there is recent evidence that CYN has teratogenic [25] and reproductive Int. J. Environ. Res. Public Health 2012, 9 
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effects [26], and there is preliminary evidence that it may be carcinogenic [20,22,27]. In these 
circumstances a reasonable additional uncertainty factor of 2 is applicable. 
Step 1: TDI = 30 ÷ 200 = 0.15 μg/kg/day 
Step 2: Acceptable limit per day = 0.15 μg/kg/day × bodyweight (kg) × 1.0 (allocation factor) 
Table 2. Acceptable daily limit for cylindrospermopsin with age and bodyweight. 
Age group (years)  Average bodyweight (kg)  Acceptable daily limit (μg/day) 
≥17  74  11 
2–16  38  5.7 
Step 3: Obtain high-level consumption data for consumers aged 17 years and above and 2–16 years 
old—see Table 1. 
Step 4: Derive health guideline level (μg/kg) for cylindrospermopsin in whole seafood sample—see 
Table 3. Acceptable limit (μg/day) ÷ consumption (kg/day) (that is Step 2 ÷ Step 3). 
Table 3. Health guideline values for cylindrospermopsin toxin in seafood. 
Health Guideline Value (μg/kg of whole organism sample) 
Age group (years)  Fish  Prawns  Mussels/Molluscs 
≥17  29  29  62 
2–16  18  24  39 
Preliminary in vitro evidence suggests that deoxyCYN has similar potency to CYN, and so this 
analogue should be included in monitoring programs and toxicity assessments [28,29]. 
3.2. Microcystins 
Microcystins have been the most thoroughly investigated cyanobacterial toxin group, and is still the 
major toxin  group under investigation. The majority of human and animal microcystin-related 
poisonings worldwide have been associated with the presence of the cyanobacterial species 
Microcystis aeruginosa and M. flos-aquae. Microcystins may also be produced by species of the 
planktonic genera Anabaena, Planktothrix (Oscillatoria), Nostoc, and Anabaenopsis. 
The microcystins are a family of cyclic peptide toxins, containing seven peptide-linked amino acids, 
in which acids in L-configuration occupy two positions in the ring. A range of L-amino acids may take 
these positions, with consequences for toxicity over a range approaching ten-fold. To standardize 
guideline values, microcystins toxicity is expressed as toxicity equivalent to microcystin-LR (leucine, 
arginine) [6]. 
The most significant recorded human poisoning event due to microcystins occurred in Brazil in 
1996 at the Caruaru Dialysis Clinic [30]. Cyanobacterial toxins contaminated the clinic’s water source, 
so that intravenous exposure to microcystins and cylindrospermopsins during routine renal dialysis 
treatment led to acute liver failure in 100 patients and resulted in 76 deaths [30]. An Australian study 
has revealed toxic liver damage (an increase in the activity of the hepatic enzyme–glutamyl-transferase) 
coincided with a bloom of M. aeruginosa in 1981 in a drinking water supply in Armidale NSW [31,32]. 
At lower doses there is also evidence that microcystin’s effects on cell regulation may increase the Int. J. Environ. Res. Public Health 2012, 9 
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growth rate of existing tumours (tumour promotion) [33]. This evidence has been provided by both 
experimental and epidemiological studies [34] with microcystins and nodularins implicated in tumour 
promotion in both the liver [35,36] and colon [37]. However, reliable dose-response data for studies 
recording human exposure to microcystins is lacking, therefore animal studies must be relied upon to 
derive a TDI. 
The only animal study that has met the OECD criteria for subchronic oral toxicity assessment in rodents 
is that of Fawell et al. (1994) [38]. Their 13-week oral gavage study of mice exposure met the criteria for 
experimental design, duration of exposure and used both sexes of animal. Fawell et al. (1994) concluded 
that the NOAEL for microcystin-LR was 40 μg/kg/day. This is supported by an oral toxicity study carried 
out in pigs, which resulted in a Lowest Observable Adverse Effect Level (LOAEL) of 100 μg/kg/day of 
microcystin-LR equivalents [6].  The International Agency for Research on Cancer has recently 
classified microcystin-LR as a “possible human carcinogen” (Class 2B) [39]. The cited mechanism of 
action is protein phosphatase inhibition and so the assumption of a threshold dose below that no 
adverse effect occurs still applies. It is appropriate, therefore, to derive a TDI from the NOAEL. 
Thus using 40 μg/kg/day as the NOAEL, the TDI for microcystin-LR (and equivalent toxins) can be 
calculated: 
TDI (μg/kg/day) = 40 μg/kg/day ÷ uncertainty factors  (5) 
The uncertainty factors are 10 for intraspecies variability, 10 for interspecies variability, and an 
additional factor of 2 for limitations in data, including evidence of tumour promotion, suspicion of 
carcinogenesis [39], conflicting data in teratogenesis, and recent evidence of reproductive toxicity. 
Step 1: TDI = 40μg/kg/day ÷ 200 = 0.2μg/kg/day. 
Step 2: Acceptable limit per day = 0.2μg/kg/day × bodyweight( kg) × 1.0 (allocation factor) 
Table 4. Acceptable daily limit for microcystins with age and bodyweight. 
Age group (years)  Average bodyweight (kg)  Acceptable daily limit (μg/day) 
≥17  74  14.8 
2–16  38  7.6 
Step 3: Apply high level consumption data from Table 1. 
Step 4: Derive health guideline level for seafood for microcystin-LR and similar toxins. 
Table 5. Derived health guideline values for microcystins in seafood. 
Health Guideline Value (μg/kg of whole organism sample) 
Age group (years)  Fish  Prawns  Mussels/Molluscs 
≥17  39  39  83 
2–16  24  32  51 
3.3. Nodularin 
Nodularin is a hepatotoxin produced by Nodularia spumigena. N. spumigena is primarily regarded 
as a brackish water species and forms blooms in estuarine lakes in Australia and New Zealand and in 
the Baltic Sea in Europe [40]. In addition to these saline environments, there have also been frequent Int. J. Environ. Res. Public Health 2012, 9 
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blooms in the freshwater lakes of the lower River Murray in South Australia [41]. As a brackish water 
species N. spumigena is the most common toxic cyanobacterial species in the Gippsland Lakes. 
Nodularin is structurally very similar to microcystin and has a similar mode of toxicity showing the 
same hepatotoxic effects through the inhibition of protein phosphatases [42]. Some have suggested it 
may be more carcinogenic than microcystin [43]. No human poisonings have been recorded as a result 
of ingestion of N. spumigena [31] however it is  “at least as hepatotoxic as microcystins for 
intraperitoneal exposure in experimental animals and, given its identical mode of action, can be 
regarded as presenting at least the same risk to human health as microcystins if ingested in drinking 
water” [40]. Due to the structural similarities between microcystins and nodularin and the lack of 
animal studies looking at the health effects associated with exposure to nodularin it is acceptable that 
the guideline value for microcystins be applied to nodularin. Several published risk assessments have 
used a similar approach [5,44]. For calculations, refer to the ‘Microcystins’ section above. 
3.4. Saxitoxins 
There have been no recorded cases of human poisonings as a result of ingestion of saxitoxins 
produced by cyanobacteria [6]. There are, however, documented cases where saxitoxins arising from 
dinoflagellates have led to neurotoxic effects as well as death in humans [45]. The established health 
guideline value for saxitoxins produced by dinoflagellates is 0.8 mg/kg (STX toxicity equivalents) in 
bivalve mussels (shellfish). This value is used by Food Standards Australia New Zealand (FSANZ 
Food Standard 1.4.1) and the Victorian Shellfish Quality Assurance Program [46]. 
Cyanobacteria produce different analogues of saxitoxin as compared to microalgae. In the U.S. 
Aphanizomenon produces saxitoxins, however the only known cyanobacterial producer in Australia is 
Anabaena circinalis [47]. Current evidence suggests that this species produces mainly the less toxic  
C-toxin analogues, along with lesser amounts of the more toxic analogues commonly found in marine 
microalgae. However, it is known that acidic or alkaline conditions and heat can chemically convert 
the C-toxins to the more toxic variants, and that similar bioconversions can occur within shellfish [48]. 
There is currently no information on the degree of inter-conversion that occurs from these low toxicity 
variants to the more toxic ones during cooking or digestion in the stomach, although it is known that 
the more toxic variants are stable at normal cooking temperatures [49]. 
The health guideline value of 0.8 mg/kg is a long-standing limit that has been used for marine 
saxitoxins. There has been a long history of success (nearly 50 years) associated with this level, with 
no evidence of human illnesses from commercially harvested products [45]. Weckell et al. attempted 
to trace the origin of the guideline value and noted that it originated from a U.S. Marine Biotoxins 
Program [7]. The limit was established in the 1930s ‘based on bioassays measuring toxic activity in 
mice’, but the exact details of its derivation are uncertain [7]. Despite this, the saxitoxin guideline 
value has been used by all major regulatory agencies around the world for many years and it does 
appear to be protective of public health [7]. 
However, in 2009 the European Food Safety Authority (EFSA) was asked by the European 
Commission to review the existing ML for saxitoxin. Following a review of published literature EFSA 
established an ARfD for saxitoxin of 0.5 μg saxitoxin equivalents/kg bw based on human data [49]. 
Together with an estimate of acute dietary intake for shellfish, EFSA revised the ML down to   Int. J. Environ. Res. Public Health 2012, 9 
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75 μg STX equivalents/kg shellfish meat. As the existing saxitoxin ML of 0.8 mg/kg in the Food 
Standards Code has a long history of effective protection for human health, this substantial downward 
revision is under further consideration. 
4. Summary 
Our conclusions may be summarized by Table 6. 
Table 6.  Health guideline values for cyanobacterial  toxins in seafood (based on 
consumption by 2–16 year age group). 
Toxin 
Health guideline value  
(μg/kg of whole organism sample) 
Fish  Prawns 
Mussels or 
Molluscs 
Cylindrospermopsin and deoxyCYN  18  24  39 
Microcystin-LR* or equivalent  
toxins, incl. Nodularin 
24  32  51 
Saxitoxins  800  800  800 
* The guideline value represents the sum value of all microcystins and nodularin present. 
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